Drug Profile
Research programme: CAR peptide therapeutics - VBS Pharmaceuticals
Alternative Names: CAR-decorin; CAR-peptides; CARSKNKDCLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator VBS Pharmaceuticals
- Class Antineoplastics; Peptides
- Mechanism of Action Immunomodulators; TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia; Kidney disorders; Scars; Sepsis; Triple negative breast cancer; Wounds
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cachexia in USA (Parenteral)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Kidney-disorders in USA (Parenteral)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Scars in USA